Skip to main content
. 2012 May 5;71(11):1872–1880. doi: 10.1136/annrheumdis-2011-201180

Table 1.

SuperAnxA1 reduces the severity of inflammatory arthritis

Time (days) Vehicle control SuperAnxA1 AnxA1
0 0% (0/6) 0% (0/6) 0% (0/6)
6 100% (6/6) 83.3% (5/6) 100% (6/6)
10 100% (6/6) 50% (3/6) 100% (6/6)

Data report the number of mice with a severe arthritic score taking a threshold of ≥8. SuperAnxA1 or AnxA1 was given from day 2 at daily doses of 1 µg intraperitoneally; the K/BxN arthritogenic serum was given on day 0 and day 2 at volumes of 50 µl each time.